131 related articles for article (PubMed ID: 26284262)
21.
McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
[TBL] [Abstract][Full Text] [Related]
22. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
23. Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.
Horwacik I; Golik P; Grudnik P; Kolinski M; Zdzalik M; Rokita H; Dubin G
Mol Cell Proteomics; 2015 Oct; 14(10):2577-90. PubMed ID: 26179345
[TBL] [Abstract][Full Text] [Related]
24. WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
Inge TH; Harris NL; Wu J; Azizkhan RG; Priebe W
J Surg Res; 2004 Oct; 121(2):187-96. PubMed ID: 15501458
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
[TBL] [Abstract][Full Text] [Related]
26. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
27. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
28. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
29. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
Saleh MN; Stapleton JD; Khazaeli MB; LoBuglio AF
J Immunol; 1993 Sep; 151(6):3390-8. PubMed ID: 8376782
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
[TBL] [Abstract][Full Text] [Related]
31. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Nov; 3(11):1969-76. PubMed ID: 9815586
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
34. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
35. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
36. Silencing of the
Bugara B; Durbas M; Kudrycka M; Malinowska A; Horwacik I; Rokita H
Front Pharmacol; 2024; 15():1351536. PubMed ID: 38495105
[TBL] [Abstract][Full Text] [Related]
37. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
Mujoo K; Reisfeld RA; Cheung L; Rosenblum MG
Cancer Immunol Immunother; 1991; 34(3):198-204. PubMed ID: 1756537
[TBL] [Abstract][Full Text] [Related]
38. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
39. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
40. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]